Salix Wins Jury Verdict In Breach Suit Over Napo Drug

Law360, Los Angeles (February 25, 2014, 5:56 PM EST) -- A New York state jury decided on Tuesday that Salix Pharmaceuticals Inc. met its contractual obligations in commercializing anti-diarrheal drug crofelemer and thus didn't breach a license agreement with Napo Pharmaceuticals Inc., as the partner's suit alleged, according to the defendant.

After a two-week trial, five of the six jurors rejected Napo’s claims of material breach and awarded no damages, with the verdict favoring Salix over claims that it failed to use commercially reasonable efforts to market and sell crofelemer, Salix's attorneys said.

Napo alleged that...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.